Clinico-pathological profile of paediatric patients with thalassemia major

Sharma S.1, Tikkas R.2, Uikey R.3, Kumar V.4

1Dr. Shweta Sharma, Associate Professor, 2Dr. R. Tikkas, Professor, 3Dr. Rajni Uikey, Postgraduate, 4Dr. Vinay Kumar, Postgraduate, All the authors are affiliated with the Department of Pediatrics, Gandhi Medical College, Bhopal, Madhya Pradesh, India

Corresponding Author: Dr. R. Tikkas, Professor, Department of Pediatrics, Gandhi Medical College, Bhopal, Madhya Pradesh, India. E-mail: raj_tikkas@rediffmail.com

Abstract

Background: The average prevalence of beta-thalassemia major is 3-4% which translates to 35-45 million carriers. Repeated use of blood transfusion in these patients causes significant morbidity and associated adverse effects. Aims and Objective: To study the clinical profile and laboratory parameters of Thalassemia major patients between the age group 1-14 years. Methodology: A Descriptive Observational study was done on 101 children of Beta-thalassemia major patients aged between 1-14 yr being regularly transfused at the Department of Pediatrics, Kamla Nehru Hospital, Gandhi Medical College, Bhopal, during the study period of March 2017 to Feb 2018. This included history, anthropometry, clinical examinations (general and systemic examinations) and laboratory Investigations including serum ferritin. RESULT: result showed that 42% patients were found to be underweight, 26.73% were short stature, 31.68% were hypocalcemic, 44.5% had low serum alkaline phosphatase. Transfusion frequency and serum ferritin were less in 1-5 years. A significant correlation was observed between the size of the spleen and the level of ferritin. CONCLUSION: Hereby it can be concluded that early diagnosis of the disease and early institution of chelation therapy can improve the life expectancy of the Beta-thalassemia patients.

Keywords: Beta-thalassemia, Ferritin, Splenomegaly, Chelation, Transfusion

Introduction

Thalassemia refers to a group of disorders of globin chain production in which there is an imbalance between the α-globin and β-globin chains, which results in a relative excess of the α-globin chain. β-Thalassemia major refers to the severe form of β-Thalassemia which requires early blood transfusion therapy and often is homozygous for β mutations. According to WHO 3.3% is the average frequency of Thalassemia carriers in India. In the state of Madhya Pradesh high prevalence of β-Thalassemia trait (20.70%) is observed [1]. Over the past three decades, regular blood transfusions and iron chelation have dramatically improved the quality of life and transformed Thalassemia major from a rapidly fatal disease in early childhood to a chronic disease compatible with prolonged life. Today life expectancy varies between 25-55 years, depending on the compliance with medical treatment.

Endocrine functions of Thalassemic children progressively decline with age secondary to hemosiderosis and nutritional deficiencies, resulting in multiple endocrinopathies like hypothyroidism, growth hormone deficiency, delayed puberty, diabetes mellitus and osteoporosis.

So, all these children require regular monitoring of endocrine functions after 5 years of age, and regular monitoring of height, weight semi-annually.

Aims and Objectives

To study the clinical profile and laboratory parameters of Thalassemia major patients between age group 1-14 years.

Material and Method

Type of study: It was a Descriptive- Observational study carried out in the Department of Pediatric Medicine, Kamla Nehru Hospital in collaboration with the Department of Biochemistry, Department of Pathology and Department of Microbiology of GMC, Bhopal, (M.P). Within 12 months from March 2017 to February 2018.

Sample collection and methods: This study was conducted on 101 children with β-Thalassemia major patients aged between 1-14 year being regularly transfused at the Department of Pediatric Medicine, Kamla Nehru Hospital, Gandhi Medical College Bhopal, (M.P.). A preformed and pre-checked proforma was used for data collection that included personal information, data regarding the number of transfusions and pre-transfusion
haemoglobin and serum ferritin, at what dose of chelators they were with clinical examination finding and laboratory investigation reports.

The current study has collected the data by using predesigned and pretested proforma which was fulfilling the objective of the study.

A unique ID was given to each patient. A detailed history of all the registered patients including personal data, history of consanguineous marriage, nutrition, frequency of transfusion, use of iron-chelating agent including dose, duration and compliance).

A thorough physical examination was performed including anthropometry, general examination and systemic examination and was recorded in the proforma.

Following anthropometric measurements were recorded: Weight, Length/Height, and mid-upper-arm circumference using standard methods.

Anthropometry details (weight, height and mid-upper arm circumference) were reviewed as per WHO criteria and patients were classified accordingly in SAM and MAM category.

Transfusion index is calculated by the formula blood volume received in ml/kg/month.

The serum ferritin level was measured in all Thalassemic patients. Iron chelating agents were advised to all patients with serum ferritin level above 1000 ng/ml.

Haemoglobin was measured before transfusion by Sahli's method. Blood group cross-matching was done by blood typing.

Standard references were used. Data regarding various clinical and laboratory parameters were recorded and tabulated and presented as frequency, percentage and mean.

**Result**

Table 1 represented the distribution of cases according to sex. 66.34% of cases were males, whereas 33.66% of cases were females.

**Table-1: Distribution of cases according to sex.**

| Sex      | No of cases (N=101) | Percent |
|----------|---------------------|---------|
| Females  | 34                  | 33.66   |
| Males    | 67                  | 66.34   |

**Inclusion criteria**

All the diagnosed β-Thalassemia major patients between the age group of 1 to 14 years attending the Department of Pediatric medicine, Kamla Nehru Hospital, Gandhi Medical College, Bhopal, (M.P.).

**Exclusion criteria**

1. Patients are less than one year and more than 14 years of age group.
2. Children having multiple congenital anomalies along with Thalassemia major.
3. Coexisting cardiac or pulmonary disease.
4. Chronic haemolytic anaemia, other than β-Thalassemia major.
5. Thalassemia minor
6. Beta-thalassemia with any other haemolytic anaemia

**Ethical permission:** The study was performed after obtaining proper ethical clearance from the respective ethical committee.

**Statistical analysis:** The data collected were analysed with Graph Ped statistical software version 7.0. Continuous variables were presented as mean for parametric data.

The student t test was applied for the calculation of statistical significance whenever the data followed normative distribution.

Nominal categorical data between the groups have been compared using Chi-square test or Fisher's exact test as appropriate.

P <0.05 was taken to indicate a statistically significant difference. Correlational analysis was done by calculating the correlation coefficient.
Fig-1 Showing distribution of patients according to Body Mass Index (BMI) (n=51).

Table-2: Showing distribution of patients according to Height for age (n=101).

|               | Short stature (below 3rd centile) | Normal stature  |
|---------------|-----------------------------------|-----------------|
| Male          | 19 (38%)                          | 48 (47.52%)     |
| Female        | 08 (16%)                          | 26 (25.74%)     |
| Total         | 27 (26.73%)                       | 74 (73.26%)     |

Fig-02: Serum Calcium values in Thalassemic patients(mg/dl).

Table-3 Serum Phosphorus values (mg/dl).

| Age (Years) | Decreased | Normal | Increased | Total   |
|-------------|-----------|--------|-----------|---------|
| 1-3         | 15 (60%)  | 04(16%)| 06(24%)   | 25 (24.75%)|
| 4-11        | 23 (36.50%)| 15(23.80%)| 25(39.68%)| 63 (62.37%)|
| 12-14       | 01 (7.69%)| 07(53.84%)| 05(38.46%)| 13 (12.87%)|
| Total       | 39        | 26     | 35        | 101     |
Table-4: Serum Alkaline Phosphatase (I/U).

| Age (Yr) | Normal | Increased | Total |
|----------|--------|-----------|-------|
| <8       | 43 (61.42%) | 27 (38.57%) | 70 (69.30%) |
| >8       | 07 (22.58%)  | 24 (77.41%)  | 31 (30.69%)  |
| Total    | 50     | 51        | 101   |

Fig-3: Renal functions in thalassemia major patients(mg/dL).

Fig-4: Liver Enzymes in Thalassemic patients(U/L).

Table-5: Correlation of liver function test, renal function test with serum ferritin.

| Dependent Indices | Correlation to Serum ferritin (R-square) | p-Value |
|-------------------|----------------------------------------|---------|
| SGOT              | 0.01056                                | p>0.05  |
| SGPT              | 0.003635                                | p>0.05  |
| Serum Bilirubin Total | 0.0338                              | p>0.05  |
| Serum Bilirubin Direct | 0.000187                          | p>0.05  |
| Total Serum Protein | 0.01235                                | p>0.05  |
| Serum Albumin     | 0.01714                                | p>0.05  |
| Serum Urea        | 0.0137                                 | p>0.05  |
| Serum Creatinine  | 0.006981                                | p>0.05  |
Table-06: Showing correlation of Hepatomegaly with transfusion index and different range of serum ferritin in all three groups.

| Age Group (N=50) | S. Ferritin | Transfusion Index |
|------------------|--------------|------------------|
| 1-5 years        |              |                  |
| <500-1000        | 8.3±5.3 cm   | r = -0.899       |
| (n=4/10)         |              | p = 0.0004       |
| 1001-1500        | 8.67±2.65 cm | r = -0.164       |
| (n=13/21)        |              | p = 0.479        |
| 1501-2000        | 9.36±2.63 cm | r = 0.308        |
| (n=6/7)          |              | p = 0.502        |
| >2000            | 9.38±1.83 cm | r = -0.235       |
| (n=10/12)        |              | p = 0.461        |
| 6-10 years (N=33)|              |                  |
| <500-1000        | 8.33±2.12 cm | r = -0.535       |
| (n=7/9)          |              | p = 0.138        |
| 1001-1500        | 9.91±1.27 cm | r = -0.180       |
| (n=3/3)          |              | p = 0.885        |
| 1501-2000        | 11.17±4.54 cm| r = -0.091       |
| (n=3/3)          |              | p = 0.942        |
| >2000            | 10.47±2.71 cm| r = -0.163       |
| (n=16/18)        |              | p = 0.519        |
| 11-14 years (N=18)|              |                  |
| <500-1000        | 8.5±0.7 cm   | r = NA           |
| (n=2/2)          |              | p = NA           |
| 1001-1500        | 9.75±2.99 cm | r = -0.821       |
| (n=3/4)          |              | p = 0.179        |
| 1501-2000        | 8.8±2.8 cm   | r = 0.492        |
| (n=4/5)          |              | p = 0.395        |
| >2000            | 8.86±3.39 cm | r = -0.479       |
| (n=6/7)          |              | p = 0.276        |

Table-07: Showing correlation of different grades of splenomegaly with serum ferritin and transfusion index.

| Spleen Size | 1-5 years | 6-10 years | 11-14 years | Serum Ferritin | Transfusion Index |
|-------------|-----------|------------|-------------|----------------|------------------|
| < 2 cm      | 03        | 02         | 00          | r = 0.1109     | r = -0.1651      |
|             |           |            |             | p = 0.6938     | p = 0.5565       |
|             |           |            |             | (2517±2274)    | (41.11±86.14)   |
| 2-7 cm      | 31        | 16         | 05          | r = -0.1242    | r = -0.04663     |
|             |           |            |             | p = 0.3805     | p = 0.7427       |
|             |           |            |             | (1966±1574)    | (37.85±78.44)   |
| >7 cm       | 11        | 15         | 08          | r = 0.4222     | R = 0.09043      |
|             |           |            |             | p = 0.0129     | p = 0.6110       |
|             |           |            |             | (2365±1949)    | (44.05±81.86)   |
Discussion

Children with β-Thalassemia major usually demonstrate no symptoms until about 2-3 months of age, when beta chains are needed to pair with alpha chains to form HbA, since gamma chains production is turned off. However, in some cases, the condition may not be recognized until 3-5 years of age due to delay in the cessation of HbF production. In the present study, at the time of enrolment, out of total 101 cases, 50 patients (49.50%) were between 1-5 years, 33 patients (32.67%) were between 6-10 years and 18 patients (17.82%) were between 11-14 years. β-Thalassemia major affects both male and female equally but gender status in the present study shows male predominance with 67 male (66.34%) and 34 (33.66%) female [2,3].

In the present study, Icterus was found to be present in 50% of cases. All the cases of this study had a normal feature which is commonly found in Thalassemic children like bony abnormalities, frontal bossing, prominent facial bones and dental malocclusion in the form of haemolysis predominance with 67 male (66.34%) and 34 (33.66%) female [2,3].

In the present study, Icterus was found to be present in 50% of cases. All the cases of this study had a normal feature which is commonly found in Thalassemic children like bony abnormalities, frontal bossing, prominent facial bones and dental malocclusion in the form of haemolytic facies were present. Oedema which can be a manifestation of both severe anemia as well as SAM was found to be present in 11 cases [4].

In the present study, 51 patients were between the age of 6 to 14 years. Among them 6 males (11.76%) and 3 females (5.88%) were underweight which accounts for 17.64% of total cases as per WHO BMI charts, while 25 cases (49.01%) of males and 17 cases (33.33%) of females were having normal BMI. None of them was found to be overweight. In the present study, there were 27 (26.73%) patients who have been found short stature on the growth chart, out of which 19 cases (38%) were boys and 08 cases (16%) were girls which showed that, short stature was more in boys as compared to girls. The current study had a lower percentage of short stature as compared to Quaish Abdullal Salehe et al study in the year 2015, in which, 79% of the β-thalassemia patients had short stature [2,5].

In patients with β-thalassemia, low bone marrow density and fractures occur frequently and independently of the particular syndrome. In less than 08 years, 16 (22.85%) cases had high i.e. hypercalcemia, 15 (21.42%) cases had low i.e. hypocalcemia and 39 (55.71%) cases were having normal levels of serum calcium. In greater than 08 years, 03 (9.67%) cases had hypercalcemia, 04 (12.90%) cases had hypocalcemia and 24 (23.76%) cases had a normal level of serum calcium. This showed that thalassemic patients who were less than 08 years of age were more hypercalcemic as compared to patients more than 08 years of age. Similarly, hypocalcemia was seen more in thalassemic patients below 08 years of age.

In 1-3 years, cases, 15 (60%) had low, 06 (24%) had high and 04 (16%) had a normal level of serum phosphorus. In 4-11 years, 23 (36.50%) cases had low, 25 (39.68%) cases had high and 15 (23.80%) cases had normal serum phosphorus levels. In 12-14 years, the only single case had hypophosphatemia, 05 (38.46%) cases had high and 07 (53.84%) cases had a normal level of Serum Phosphorus [6,7,8,9]. The present study found 39 cases to have hypophosphatemia which account for 38.61%, which may be due to renal function derangements and abnormality of bone marrow turnover [10,11].

Renal profile of the patients showed almost 1/3rd cases 31(30.69%) case had high levels of creatinine, rest were having normal levels. Serum urea was high in 65(64.35%) cases [12,13,14,15,16]. Though most of the urea and creatinine were only mildly elevated which may be due to chelator therapy in the higher age group.

In the present study, 50 patients of 1 to 5 years of age, 33(66%) patients showed hepatomegaly with the mean liver span of 8.86±3.14 cm. and mean serum ferritin 1584±1116. There was a positive correlation with serum ferritin concentration, transfusion index with respective correlation coefficients (r) of 0.167, 0.1552 and 0.478. Correlation of hepatomegaly with Transfusion index (p<0.0001) and was statistically significant. Mean serum ferritin found in 06 to 10 years age group was 2976+/-2211 and was also having p value 0.026.

In the present study, liver, span in patients of 1-5 years of age group was correlated significantly in serum ferritin levels less than 1000 ng/ml with transfusion index (p=0.0004) [17].

Conclusion

There is a direct adverse impact of increasing serum ferritin values and transfusion index on anthropometric, clinical parameters and the biochemical parameters.

What does the study add to the existing knowledge?

early estimation of serum ferritin and early institution of chelation therapy will have a better quality of life and can prevent complications in beta-thalassemia major patients.

Author’s contributions

Dr. Shweta Sharma: Concept, study design
Dr. R. Tikkas: Manuscript preparation
Dr. Rajni Uikey: Data analysis
Dr. Vinay Kumar: Data analysis
Funding: No funding sources

Conflict of interest: None declared

Ethical Approval: This study was approved by the Institutional Ethics Committee

References

1. Thakur S, Sharma R, Sharada R. Incidence of Thalassemia and Sickle Cell Disease in Chhattisgarh, Central India: Using Hardy-Weinberg Equations. J Mol Gen Med. 2014;9:155. doi: https://doi.org/10.4172/1747-0862.1000155.

2. Al-Salehe QAA, Al-Awady MS, Abbass SK. Growth Retardation In B-Thalassemia Major: Iraqi PG Med J. 2015;14(2).

3. Shah N, Mishra A, Chauhan D, Vora C, Shah NR. Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India. Asian J Transfus Sci. 2010;4(2):94-98. Available from: http://www.ajts.org/text.asp?2010/4/2/94/67029.

4. Hassan MY, Max J Coppes: emedicine, Medscape; Aug 23, 2017. Available from https://emedicine.medscape.com/article/958850-clinical.

5. Ali S, Jahan S. Growth Failure in β-Thalassemia major Patients Undergoing Repeated Transfusions. JIIMC. 2016;11 (3):120-124.

6. El-Nashar M, Mortagy AK, El-Beblawy NM, El-Gohary E, Kamel IM, Rashad M, et al. Parathyroid hormone in pediatric patients with β-thalassemia major and its relation to bone mineral density: a case control study. Egypt J Med Human Genet. 2017;18(1):75-78. doi: http://dx.doi.org/10.1016/j.ejmhg.2016.03.004.

7. Goyal M, Abrol P, Lal H. Parathyroid and Calcium Status in Patients with Thalassemia. Indian J Clin Biochem. 2010;25(4):385-387. doi: https://dx.doi.org/10.1007%2Fs12291-010-0071-5.

8. Vogiatzi MG, Autoi KA, Mait JE, Schneider R, Lesser M, Giardina PJ. Low bone mineral density in adolescents with β-thalassemia. Annals New York Acad Sci. 2005;1054(1):462-466. doi: https://doi.org/10.1196/annals.1345.063.

9. Soliman A, Sanctis VD, Yassin M. Vitamin D Status in Thalassemia Major: an Update. Mediterr J Hematol Infect Dis. 2013;5(1):e2013057. doi: https://dx.doi.org/10.4084%2FMJHID.2013.057.

10. Teli AB, Deori R, Saikia SP, Pathak K, Panyang R, Rajakakati R. β-Thalassaemia and its Co-existence with Haemoglobin E and Haemoglobin S in Upper Assam Region of North Eastern India: A Hospital Based Study. J Clin Diagn Res. 2016;10(4):GC01-GC04. doi: https://doi.org/10.7860/JCDR/2016/16265.7675.

11. Sultan S, Irfan SM, Ahmed SI. Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan. Advan Hematol. 2016. doi: https://doi.org/10.1155/2016/5437609.

12. Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, et al. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol. 2008;23(10):1847-1851. doi: https://doi.org/10.1007/s00467-008-0897-8.

13. Jalali A, Khalilian H, Ahmadzadeh A, Sarvestani S, Rahim F, Zandian K, et al. Renal function in transfusion dependent pediatric beta-thalassaemia major patients. Hematol. 2011;16(4):249-254. doi: https://doi.org/10.1179/102453311X12953015767662.

14. Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Italian J Pediatr. 2010;36:39. doi: https://doi.org/10.1186/1824-7288-36-39.

15. Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, et al. Renal dysfunction in patients with thalassemia. Br J Haematol. 2011;153(1):111-117. doi: https://dx.doi.org/10.1111%2Fj.1365-2451.2010.08477.x.

16. Lai ME, Spiga A, Vacquer S, Carta MP, Corrias C, Ponticelli C. Renal function in patients with β-thalassaemia major: a long-term follow-up study. Nephrol Dial Transplant. 2012;27(9):3547-3551. doi: https://doi.org/10.1093/ndt/gfs169.

17. Mishra AK, Tiwari A. Iron Overload In Beta Thalassaemia Major And Intermedia Patients. Maedica: J Clin Med. 2013;8(4):328-332.

How to cite this article?

Sharma S, Tikkas R, Uikey R, Kumar V. Clinico-pathological profile of paediatric patients with thalassemia major. Int J Pediatr Res. 2020;7(2): 49-55. doi:10.17511/ijpr.2020.i2.01